Gyre Therapeutics, Inc.
GYRE
$7.01
-$0.64-8.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -147.73% | 716.74% | -83.62% | 2,825.25% | -108.81% |
| Total Depreciation and Amortization | 7.09% | 1.25% | 19.81% | 7.00% | 12.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.26% | 92.23% | -34.58% | 245.12% | -64.62% |
| Change in Net Operating Assets | -300.37% | -410.50% | 91.54% | -47.47% | -124.81% |
| Cash from Operations | -220.30% | 123.95% | 1,718.60% | 95.32% | -259.79% |
| Capital Expenditure | 78.44% | -160.94% | -109.84% | -287.69% | 109.38% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 1,700.00% | -99.28% | 2,860.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 442.14% | 79.35% | -234.29% | 194.61% | -30.67% |
| Cash from Investing | 248.20% | 59.01% | -254.65% | 198.15% | 16.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 536.00% | -99.79% | 1,540.41% | 10.07% | 255.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 118.74% | -1,289.26% | 67.03% | -634.00% |
| Cash from Financing | -12.88% | -98.37% | 1,563.02% | 39.42% | 197.53% |
| Foreign Exchange rate Adjustments | 8.55% | 138.78% | -2.00% | 119.61% | -340.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -185.20% | -81.76% | 563.55% | 179.74% | -1,654.55% |